These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

775 related items for PubMed ID: 26015278

  • 1. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C.
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [Abstract] [Full Text] [Related]

  • 2. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N, Ayer M, Ergen A, Ozturk S.
    Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
    [Abstract] [Full Text] [Related]

  • 3. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [Abstract] [Full Text] [Related]

  • 4. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D, Yu XJ, Wang FM, Xu BN, He YD, Chen Q, Wang SX, Yu F, Song WC, Zhao MH.
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [Abstract] [Full Text] [Related]

  • 5. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
    Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Suñer M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, Rodriguez de Cordoba S.
    Kidney Int; 2018 Feb; 93(2):450-459. PubMed ID: 28911789
    [Abstract] [Full Text] [Related]

  • 6. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [Abstract] [Full Text] [Related]

  • 7. Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report.
    Kurihara S, Yamaguchi A, Sonoda K, Yamada Y, Harada M, Hashimoto K, Shimojo H, Ikeda Y, Kamijo Y.
    BMC Nephrol; 2024 Jul 15; 25(1):224. PubMed ID: 39009967
    [Abstract] [Full Text] [Related]

  • 8. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
    Hofer J, Giner T, Józsi M.
    Semin Thromb Hemost; 2014 Jun 15; 40(4):431-43. PubMed ID: 24799303
    [Abstract] [Full Text] [Related]

  • 9. An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome.
    Fung WW, Chao AC, Pang WF, Wong RS, Chow KM, Szeto CC.
    BMC Nephrol; 2024 May 14; 25(1):164. PubMed ID: 38745129
    [Abstract] [Full Text] [Related]

  • 10. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R.
    Ther Apher Dial; 2018 Apr 14; 22(2):178-188. PubMed ID: 29250893
    [Abstract] [Full Text] [Related]

  • 11. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea.
    Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D.
    J Korean Med Sci; 2016 Oct 14; 31(10):1516-28. PubMed ID: 27550478
    [Abstract] [Full Text] [Related]

  • 12. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan 14; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

  • 13. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
    Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D.
    Kidney Int; 2017 Nov 14; 92(5):1261-1271. PubMed ID: 28750931
    [Abstract] [Full Text] [Related]

  • 14. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G.
    Pediatr Nephrol; 2016 May 14; 31(5):759-68. PubMed ID: 26604087
    [Abstract] [Full Text] [Related]

  • 15. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab.
    Barlas UK, Kıhtır HS, Goknar N, Ersoy M, Akcay N, Sevketoglu E.
    Pediatr Nephrol; 2018 Jun 14; 33(6):1093-1096. PubMed ID: 29558000
    [Abstract] [Full Text] [Related]

  • 16. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship TH, Kavanagh D, Unsal A.
    J Med Case Rep; 2015 Apr 29; 9():92. PubMed ID: 25925370
    [Abstract] [Full Text] [Related]

  • 17. First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis.
    Szarvas N, Szilágyi Á, Tasic V, Nushi-Stavileci V, Sofijanova A, Gucev Z, Szabó M, Szabó A, Szeifert L, Reusz G, Rusai K, Arbeiter K, Müller T, Prohászka Z.
    Ital J Pediatr; 2014 Dec 11; 40():101. PubMed ID: 25496981
    [Abstract] [Full Text] [Related]

  • 18. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.
    Am J Kidney Dis; 2019 Jul 11; 74(1):56-72. PubMed ID: 30851964
    [Abstract] [Full Text] [Related]

  • 19. Complement Activation and Thrombotic Microangiopathies.
    Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M.
    Clin J Am Soc Nephrol; 2019 Dec 06; 14(12):1719-1732. PubMed ID: 31694864
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec 06; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.